ARScience Biotherapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ARScience Biotherapeutics is a private, clinical-stage biotech focused on engineering customized interleukins to enhance and modulate immune responses. The company leverages over 20 years of collective team experience in cytokine development and has established a key licensing partnership with Coya Therapeutics for its lead low-dose IL-2 candidate, COYA 301. ARScience aims to partner with cell therapy companies (e.g., CAR-T, NK cells) and pharmaceutical firms to provide cytokine components that improve the efficacy of advanced immunotherapies.

OncologyAutoimmune Diseases

Technology Platform

Platform for engineering and manufacturing customized interleukin proteins with tailored immune-modulating properties for therapeutic use and combination with cell therapies.

Opportunities

The growing cell therapy market creates a major B2B opportunity for engineered cytokines as combination agents to enhance efficacy.

There is also significant unmet need for safer, more effective cytokine therapeutics in oncology and autoimmune diseases, driving demand for next-generation engineered interleukins.

Risk Factors

High competition in cytokine engineering from well-funded rivals, technical risk of failing to create effective and safe modified proteins, and dependence on a partnership-driven business model that requires convincing cell therapy developers to adopt external components.

Competitive Landscape

ARScience competes in the cytokine engineering space with companies like Nektar, Alkermes, Sobi, Synthorx (Sanofi), and Werewolf Therapeutics. Its focus on partnering for cell therapy combinations is a differentiating angle, but it must compete on the potency and specificity of its engineered molecules.

More companies in Biologics / Biosimilars →More companies in United States →